Navigation Links
Stallergenes Moves to the Cloud With Veeva CRM
Date:10/11/2011

BARCELONA, Spain, October 11, 2011 /PRNewswire/ --

Leading Specialty Pharmaceutical Company Consolidates Four On-Premise CRM Systems into One

Stallergenes, the world leader in sublingual immunotherapy, has selected Veeva CRM to replace its existing conventional on-premise systems to support its worldwide sales force. Veeva CRM is today's #1 selling cloud-based CRM solution for the global pharmaceutical and biotech industry.

Previously, Stallergenes utilised four different Customer Relationship Management (CRM) systems across 14 countries before selecting Veeva CRM.  Veeva was chosen from a pool of CRM vendors to support Stallergenes growing international operations and new sales force effectiveness initiative. According to the company, Veeva CRM proved to be the most innovative and robust solution, enabling improved customer targeting, increased understanding of customer behaviour and enhanced coordination of data between the field force, medical affairs and marketing teams.


"We needed a system that could support rapid growth across borders," said Cyril Tavier, vice president, international operations at Stallergenes. "Veeva's cloud-based solution is the gold standard in new, innovative technologies, allowing the high level of flexibility and scalability we need to support our expanding operations globally. Veeva is a perfect match for our company, and supports our mission as an industry innovator."

Thierry Grehaigne, vice president, information technologies at Stallergenes added, "We wanted a single, comprehensive CRM solution that would be intuitive and easy to use for all users across regions and that could keep pace with changing technology. Veeva had it all."

Stallergenes will also be rolling out Veeva's leading iPad application, iRep, to users in major European markets. Veeva iRep is the first integrated CLM/CRM application designed specifically for the Apple iPad. Veeva redesigned its CRM application to leverage the many strengths of the iPad and added closed loop marketing functionality to allow seamless alignment of sales and marketing strategies and execution.

"We are very excited about how iRep will revolutionise our customer interactions by bringing us closer to our customers and being able to respond to their specific needs," added Cyril Tavier.  "The integrated CRM and CLM functionality in iRep will allow our teams to tailor marketing and medical messages to micro-segments of the market.  And, we'll have a constant feedback loop between the field force and head office." 

Over the past four years, Veeva Systems has quickly become a leading provider of CRM solutions to the global pharmaceutical industry. Because of its cloud-based platform, Veeva CRM requires no hardware or software to purchase, scale, or maintain. In addition, all Veeva customers benefit from free, automatic upgrades so users are always on the most current version of the software and benefit from the very latest compliance changes and system enhancements.

"Veeva CRM will play a pivotal role in the speed at which we develop our international operations and deliver on our new sales force effectiveness programme," said Cyril Tavier.

"Forward-thinking pharma companies throughout Europe, like Stallergenes, are realising the value in replacing limited, on-premise applications with Veeva's flexible cloud-based enterprise solution," concluded Dan Goldsmith, general manager of Veeva Europe. "We look forward to working closely with the Stallergenes team as their commercial enterprise grows."


About Stallergenes

Stallergenes is a European biopharmaceutical company dedicated to the treatment of allergy-related respiratory diseases, such as severe rhinoconjunctivitis and rhinitis, as well as allergic asthma, using allergen immunotherapy. The leader in sublingual immunotherapy treatment, Stallergenes devotes almost 20% of its gross turnover to Research & Development and is actively involved in the development of a new therapeutic class, sublingual immunotherapy tablets. In 2010, the company had a turnover of 216 million euros, and more than 500,000 patients were treated with Stallergenes products.

About Veeva CRM

The Veeva CRM suite of applications, comprised of VBioPharma, iRep, VMobile, and VInsights, is the pharmaceutical and biotechnology industry's leading cloud-based CRM solution. In addition, iRep has quickly become the industry's choice for closed loop marketing on the iPad. Only Veeva CRM accommodates the unique needs of multiple commercial teams in a single solution, improving user adoption and sales effectiveness, while reducing cost and complexity. Veeva CRM is now the foundation on which the pharmaceutical industry is adapting its sales and marketing models for the future.

About Veeva Systems

Veeva Systems is the leader in cloud-based solutions for the global life sciences industry. Committed to innovation, product excellence, and customer success, Veeva has over 100 customers, ranging from the world's largest pharmaceutical companies to emerging biotechs. Founded in 2007, Veeva is a privately held company headquartered in the San Francisco Bay Area, with offices in Philadelphia, Barcelona, Budapest, Paris, Beijing, Shanghai, and Tokyo. For more information, visit http://www.veevasystems.com

Copyright (c) 2011 Veeva Systems. All rights reserved. Veeva and the Veeva logo are registered trademarks of Veeva Systems. Veeva Systems owns other registered and unregistered trademarks. Other names used herein may be trademarks of their respective owners.

Media Contact
Selma Nawaz
European Marketing Director
Veeva Systems
selma.nawaz@veevasystems.com



'/>"/>
SOURCE Veeva Systems
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Stallergenes: New Study VO 56 Highly Positive Results Conducted in an Allergen Challenge Chamber
2. STALLERGENES: Oralair(R) Grasses Obtains a Pediatric MA(1) in Germany
3. Stallergenes S.A.: Positive Results From a Phase IIb/III Clinical Trial on the House Dust Mite Desensitization Tablet
4. Stallergenes: Oralair: Very Positive 3-Year Results of the Long-Term Study
5. STALLERGENES: Persistent Efficacy Demonstrated After a Year on Actair(R) Followed by a Second Treatment-Free Year
6. STALLERGENES: Excellent 1st Half-Year 2010 Performance
7. Arriva Pharmaceuticals Moves Forward to Phase 2b Development of Lead Inhaled Protein rAAT Replacement Therapy for Hereditary Emphysema
8. Trellis(R) Catheter Removes Blood Clots Quickly, Restoring Blood Flow in 771 Deep Vein Thrombosis (DVT) Patients
9. Neutropenia: Biosimilar Product from India Moves One Step Closer to European Market
10. Roche Moves Investigational Diabetes Drug, Taspoglutide, Into Phase III Clinical Trials
11. Debiopharm Moves Towards a New 6-Month Formulation of Decapeptyl(R) to Further Help Prostate Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... 19, 2017  Novartis today announced the publication ... Lung, and Blood Institute (NHLBI) of the National ... patients with treatment-naïve severe aplastic anemia (SAA) achieved ... eltrombopag at the initiation of and concurrently with ... three sequential treatment groups, or cohorts. Cohort 3 ...
(Date:4/18/2017)... MINNEAPOLIS , April 18, 2017 Cogentix ... focused on providing the Urology, Uro/Gyn and Gynecology markets ... for the first quarter ended March 31, 2017 after ... The Company will host a conference call ... day on Tuesday, May 2, 2017 at 4:30 p.m. ...
(Date:4/18/2017)... , April 18, 2017  Astute Medical, Inc., developer ... series to be presented at the 2017 National Kidney ... today and continues through April 22. Physicians will present ... used to assess risk for acute kidney injury (AKI) ... failure (ADHF). Elevated levels of TIMP-2 ...
Breaking Medicine Technology:
(Date:4/29/2017)... (PRWEB) , ... April 29, 2017 , ... Phytomer USA ... As a Phytomer Account Manager, Smith’s role is to provide excellent customer ... that make up The Phytomer Group. Smith comes to Phytomer with a wealth of ...
(Date:4/28/2017)... ... April 28, 2017 , ... The National Campaign to ... the Access to Contraception for Women Servicemembers and Dependents Act of 2017. The ... will help to ensure that all members of the Armed Forces receive high ...
(Date:4/28/2017)... ... April 28, 2017 , ... Horizon Blue Cross Blue Shield of New Jersey ... “A” and its outlook as “stable.” At the same time, the ratings agency cautioned ... recent years, dip below “capital adequacy” thresholds required for its strong rating. , “Horizon ...
(Date:4/28/2017)... ... April 28, 2017 , ... The Radiology Business Management ... officers for 2017-2018. The annual board election process has been in place since the ... , Thomas C. Dickerson, Ed.D., FACHE, succeeds Jim Hamilton, MHA, CMM, FRBMA, as president. ...
(Date:4/28/2017)... ... April 28, 2017 , ... ... liability could substantially improve drug safety and minimize the cost of development. In ... ion channel inhibition using cell lines and for cardiac toxicity using induced pluripotent ...
Breaking Medicine News(10 mins):